Backgrounds
BRAF is a serine/threonine kinase that belongs to the Recently, the BEACON CRC trial, which enrolled patients with previously treated unresectable The BEACON CRC trial was followed by the ANCHOR CRC trial wherein the effectiveness of the triplet regimen was evaluated in patients with previously untreated unresectable The optimal treatment strategy for resectable Accordingly, we planned a multicenter phase II clinical study to evaluate the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated but surgically resectable Schematic image of the NEXUS study